Clinical Trial Update: Safety, Tolerability and Efficacy of ACZ885 on Leg Artery Structure in Patients With Peripheral Artery Disease [Phase 2]

View source ↗

Summary

This update covers results from a Phase 2 trial evaluating ACZ885 (canakinumab) on leg artery structure in patients with Peripheral Artery Disease. The study wa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral Artery Disease

Drugs mentioned

• ACZ885 (canakinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Peripheral Artery Disease | Phase 2 | Status: TERMINATED | Results posted: 2017-08-22